Review suggests $3.5 billion prizes for antibiotic drugmakers

LONDON, May 14 (Reuters) - Companies that develop new antibiotics should be awarded prize money of up to $3.5 billion for each new drug, instead of selling the medication at a profit, a review backed by Britain's government said on Thursday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.